TITLE

G-CSF plus PBPCT offers cost-effective alternative to ABMT

PUB. DATE
November 1995
SOURCE
Formulary;Nov95, Vol. 30 Issue 11, p652
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Suggests that the combination of peripheral blood progenitor cell (PBPC) transplantation and colony-stimulating factor (G-CSF) is a cost effective treatment for Hodgin's disease or lymphoma. Comparison with autologous bone marrow transplantation costs; Comments of Thomas Smith of Virginia Commonwealth University; Shorter hospitalization entailed by the use of PBPC.
ACCESSION #
9511291452

 

Related Articles

  • Non-hodgkin's lymphoma. Patlak, Margie // FDA Consumer;Dec96, Vol. 30 Issue 10, p20 

    Reports that the Non-Hodgkin's (NHL) lymphoma is now the sixth most common cancer in the United States. Symptoms of NHL; Treatments for NHL; How doctors determine the stage of the cancer according to the number and location of tumors; What procedure is used to determine the type of NHL cancer;...

  • Discussion about treatment of early-stage Hodgkin's lymphoma needed radiation oncologist. Prosnitz, Leonard R.; Kelsey, Christopher // Hem/Onc Today;4/10/2013, Vol. 14 Issue 7, p7 

    The article discusses the highlights of a roundtable discussion about the treatment of early-stage Hodgkin's lymphoma featured on the December 25, 2013 issue of "Hematology/Oncology Today."

  • Naturopathy Complements Chemo. Bennett, Peter // Alive: Canada's Natural Health & Wellness Magazine;Apr2002, Issue 234, p46 

    Focuses on the importance of naturopathy in reducing the side effects of conventional therapy in treating Hodgkin's lymphoma. Strategies for managing health challenges; Comprehensiveness of the natural program to fight cancer; Risk of chemotherapy treatment for cancer.

  • Doxorubicin liposomal.  // Reactions Weekly;2/4/2012, Issue 1387, p17 

    The article describes the case of a 37-year-old man developed palmoplantar erythrodysaesthesia (PPE) while receiving pegylated (PLD) and non-pegylated doxorubicin (NPLD) liposomal for Hodgkin's disease.

  • Osteosarcoma in an adolescent previously treated for Hodgkin's Disease. Kourti, M.; Sidi, V.; Papakonstantinou, E. // Hippokratia;2014, Vol. 18 Issue 1, p96 

    A letter to the editor is presented which reveals the development of a secondary tumor or osteosarcoma in an adolescent after treatment for Hodgkin's disease.

  • Non-Hodgkin's lymphoma trials in elderly look beyond CHOP. McNeil, Caroline; McNeil, C // JNCI: Journal of the National Cancer Institute;02/18/98, Vol. 90 Issue 4, p266 

    Presents information on researchers' launch of a randomized trial for elderly patients with intermediate-grade non-Hodgkin's lymphoma (NHL) in December, 1997. Why this trial was launched; Indepth look at the trial; Statistical information on the increase of NHL; Comments from Joseph M. Connors,...

  • Procarbazine. Spivack, Samuel D. // Annals of Internal Medicine;Dec74, Vol. 81 Issue 6, p795 

    Deals with the developments in the use of procarbazine since its approval in 1969 for the treatment of Hodgkin's disease. Mechanism of action of the drug; Other clinical uses of the agent; Other diseases in which procarbazine is useful; Potential toxicities of the drug.

  • Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests... Radford, J.A.; Eardley, A. // BMJ: British Medical Journal (International Edition);2/1/97, Vol. 314 Issue 7077, p343 

    Investigates the effectiveness of routine clinic review in detecting relapse following treatment for Hodgkin's disease. Methodology; Outpatient review and relapse; Risk of relapse; Cause of relapse; Functions of routine review after treatment for Hodgkin's disease; Recommendations.

  • Hodgkins disease. Ferme, C; Cosset, J M; Fervers, B; Sebban, C; Cutuli, B; Henry-Amar, M; Stines, J; Giammarile, F; Bey, P; Philip, T // British Journal of Cancer;5/2/2001 Supplement 2, Vol. 84, p55 

    Focuses on the treatment strategies of Hodgkin's disease (HD). Description of standards, options and recommendations for the management of HD in 2001; Use of surgery, radiotherapy and chemotherapy for the treatment of HD.

Share

Read the Article

Other Topics